HIF-2α deletion promotes Kras-driven lung tumor development

Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths worldwide. The oxygen-sensitive hypoxia inducible factor (HIF) transcriptional regulators HIF-1α and HIF-2α are overexpressed in many human NSCLCs, and constitutive HIF-2α activity can promote murine lung tumor progression, suggesting that HIF proteins may be effective NSCLC therapeutic targets. To investigate the consequences of inhibiting HIF activity in lung cancers, we deleted Hif-1α or Hif-2α in an established KrasG12D-driven murine NSCLC model. Deletion of Hif-1α had no obvious effect on tumor growth, whereas Hif-2α deletion resulted in an unexpected increase in tumor burden that correlated with reduced expression of the candidate tumor suppressor gene Scgb3a1 (HIN-1). Here, we identify Scgb3a1 as a direct HIF-2α target gene and demonstrate that HIF-2α regulates Scgb3a1 expression and tumor formation in human KrasG12D-driven NSCLC cells. AKT pathway activity, reported to be repressed by Scgb3a1, was enhanced in HIF-2α-deficient human NSCLC cells and xenografts. Finally, a direct correlation between HIF-2α and SCGB3a1 expression was observed in approximately 70% of human NSCLC samples analyzed. These data suggest that, whereas HIF-2α overexpression can contribute to NSCLC progression, therapeutic inhibition of HIF-2α below a critical threshold may paradoxically promote tumor growth by reducing expression of tumor suppressor genes, including Scgb3a1.

[1]  John D Gordan,et al.  HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. , 2007, Cancer cell.

[2]  J. M. Arbeit,et al.  Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. , 2000, Cancer research.

[3]  Andrew L. Kung,et al.  Suppression of tumor growth through disruption of hypoxia-inducible transcription , 2000, Nature Medicine.

[4]  G. Semenza,et al.  Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. , 1994, The Journal of biological chemistry.

[5]  Pierre Baldi,et al.  A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes , 2001, Bioinform..

[6]  D. Hayes,et al.  HIF2α cooperates with RAS to promote lung tumorigenesis in mice (Journal of Clinical Investigation (2009) 119, (2160-2170) doi:101172/JCI38443) , 2009 .

[7]  R. Johnson,et al.  Acute postnatal ablation of Hif-2alpha results in anemia. , 2007, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. M. Arbeit,et al.  Hypoxia-inducible Factor-1α Is a Positive Factor in Solid Tumor Growth , 2000 .

[9]  M. Meyerson,et al.  Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. , 2004, Molecular cancer research : MCR.

[10]  Donna Richardson,et al.  Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Hayes,et al.  HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. , 2009, The Journal of clinical investigation.

[12]  Robert Tibshirani,et al.  An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Non–Small Cell Lung Cancers , 2006, Clinical Cancer Research.

[13]  A. Harris,et al.  Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival , 2001, British Journal of Cancer.

[14]  H. Sasaki,et al.  HIN-1 , an Inhibitor of Cell Growth , Invasion , and AKT Activation , 2005 .

[15]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[16]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[17]  Brian Keith,et al.  Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. , 2003, Molecular and cellular biology.

[18]  J. Mesirov,et al.  An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis , 2005, Nature Genetics.

[19]  Richard D Klausner,et al.  The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. , 2002, Cancer cell.

[20]  Mirna Lechpammer,et al.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.

[21]  P. Carmeliet,et al.  Genetic evidence for a tumor suppressor role of HIF-2alpha. , 2005, Cancer cell.

[22]  Rafael A. Irizarry,et al.  A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .

[23]  C. Holterman,et al.  Human cancers converge at the HIF-2α oncogenic axis , 2009, Proceedings of the National Academy of Sciences.

[24]  Brian Keith,et al.  HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. , 2008, Cancer cell.

[25]  G. Semenza.  HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. , 2009, Current pharmaceutical design.

[26]  R. Eisenman,et al.  Myc's broad reach. , 2008, Genes & development.

[27]  K. Lunetta,et al.  HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Livingston,et al.  Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. , 2004, Cancer cell.

[29]  D. Kwong,et al.  Promoter hypermethylation of high-in-normal 1 gene in primary nasopharyngeal carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  R. Deberardinis,et al.  The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. , 2007, Genes & development.

[31]  A. Marchetti,et al.  Down Regulation of High in Normal-1 (HIN-1) is a Frequent Event in Stage I Non-Small Cell Lung Cancer and Correlates with Poor Clinical Outcome , 2004, Clinical Cancer Research.

[32]  S. Toyooka,et al.  Aberrant methylation of HIN‐1 (high in normal‐1) is a frequent event in many human malignancies , 2005, International journal of cancer.

[33]  M. Celeste Simon,et al.  The impact of O2 availability on human cancer , 2008, Nature Reviews Cancer.

[34]  W. Kaelin,et al.  Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. , 2008, Molecular cell.

[35]  Brian Keith,et al.  Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation , 2003, Molecular and Cellular Biology.

[36]  R. Johnson,et al.  Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. , 2007, Cancer research.

[37]  Patrick H. Maxwell,et al.  Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma , 2005, Molecular and Cellular Biology.

[38]  R. Johnson,et al.  Hypoxia-Inducible Factor-1α Is a Key Regulator of Metastasis in a Transgenic Model of Cancer Initiation and Progression , 2007 .

[39]  R. Johnson,et al.  Acute postnatal ablation of Hif-2α results in anemia , 2007, Proceedings of the National Academy of Sciences.

[40]  M. Simon,et al.  Hypoxia-inducible factors: central regulators of the tumor phenotype. , 2007, Current opinion in genetics & development.

[41]  L. Chin,et al.  Expression of high in normal-1 (HIN-1) and uteroglobin related protein-1 (UGRP-1) in adult and developing tissues , 2002, Mechanisms of Development.

[42]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[43]  W. Kaelin,et al.  Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth , 2003, PLoS biology.